The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
R | Respiratory system | |
2
|
R03 | Drugs for obstructive airway diseases | |
3
|
R03B | Other drugs for obstructive airway diseases, inhalants | |
4
|
R03BX | Other drugs for obstructive airway diseases, inhalants |
| Code | Title | |
|---|---|---|
| R03BX01 | Fenspiride | |
| R03BX02 |
| Active Ingredient |
|---|
|
Ensifentrine is a small molecule that is an inhibitor of the PDE3 and PDE4 enzymes. PDE3 primarily hydrolyzes the second-messenger molecule cyclic adenosine monophosphate (cAMP) but is also capable of hydrolyzing cyclic guanosine monophosphate (cGMP). PDE4 hydrolyzes cAMP only. Inhibition of PDE3 and PDE4 results in accumulation of intracellular levels of cAMP and/or cGMP, resulting in various downstream signalling effects. |
|
Fenspiride has an anti-inflammatory and bronchodilator activity. These properties are most likely due to several concomitant mechanisms of action. It is used as symptomatic treatment in the course of inflammatory diseases of the bronchi and lungs. |
| Document | Type | Information Source | |
|---|---|---|---|
| OHTUVAYRE Inhalation suspension | MPI, US: SPL/PLR | FDA, National Drug Code (US) |